-
@ Yahoo! Finance - by layer3.news
2025-05-25 20:17:34
nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r
✍️ BofA increases price target for Merus to $92, citing favorable Phase 2 trial results for petosemtamab and pembrolizumab in treating head and neck cancer.
👉 BofA increases price target for Merus to $92
👉 Favorable Phase 2 trial results for petosemtamab and pembrolizumab in treating head and neck cancer
👉 12-month objective survival rate of 79%
👉 63% overall response rate among evaluable patients
#Netherlands #health
nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqz2as4xchsajtlm3n0gr59rsa65dnttsd26p6pyfpjfvthnmyyn0q6wac8e